Rani Therapeutics Holdings, Inc. (RANI)
0.854
+0.01
(+1.67%)
USD |
NASDAQ |
Aug 31, 15:09
Rani Therapeutics Holdings Enterprise Value : 53.21M for Aug. 28, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 28, 2026 | 53.21M |
| August 27, 2026 | 54.81M |
| August 26, 2026 | 53.37M |
| August 25, 2026 | 58.95M |
| August 24, 2026 | 57.60M |
| August 21, 2026 | 57.71M |
| August 20, 2026 | 54.45M |
| August 19, 2026 | 61.83M |
| August 18, 2026 | 51.57M |
| August 17, 2026 | 48.25M |
| August 14, 2026 | 48.27M |
| August 13, 2026 | 48.47M |
| August 12, 2026 | 49.02M |
| August 11, 2026 | 47.02M |
| August 10, 2026 | 46.11M |
| August 07, 2026 | 47.81M |
| August 06, 2026 | 46.58M |
| August 05, 2026 | 46.46M |
| August 04, 2026 | 50.96M |
| August 03, 2026 | 48.85M |
| July 31, 2026 | 45.79M |
| July 30, 2026 | 50.99M |
| July 29, 2026 | 53.65M |
| July 28, 2026 | 50.88M |
| July 27, 2026 | 49.84M |
| Date | Value |
|---|---|
| July 24, 2026 | 54.43M |
| July 23, 2026 | 58.83M |
| July 22, 2026 | 59.59M |
| July 21, 2026 | 36.45M |
| July 20, 2026 | 35.92M |
| July 17, 2026 | 37.15M |
| July 16, 2026 | 34.07M |
| July 15, 2026 | 34.87M |
| July 14, 2026 | 31.72M |
| July 13, 2026 | 29.88M |
| July 10, 2026 | 36.02M |
| July 09, 2026 | 37.26M |
| July 08, 2026 | 36.67M |
| July 07, 2026 | 38.50M |
| July 06, 2026 | 47.92M |
| July 02, 2026 | 45.48M |
| July 01, 2026 | 45.15M |
| June 30, 2026 | 44.25M |
| June 29, 2026 | 43.80M |
| June 26, 2026 | 40.93M |
| June 25, 2026 | 41.57M |
| June 24, 2026 | 44.03M |
| June 23, 2026 | 42.83M |
| June 22, 2026 | 44.60M |
| June 18, 2026 | 45.57M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Cocrystal Pharma, Inc. | 14.26M |
| CNBX Pharmaceuticals, Inc. | 1.364M |
| GB Sciences, Inc. | -- |
| Arvinas, Inc. | 39.75M |
| Fulcrum Therapeutics, Inc. | -19.86M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -8.421M |
| Revenue (Quarterly) | 1.708M |
| Total Expenses (Quarterly) | 9.099M |
| EPS Diluted (Quarterly) | -0.0395 |
| Gross Profit Margin (Quarterly) | 88.29% |
| Profit Margin (Quarterly) | -493.0% |
| Earnings Yield | -31.05% |
| Normalized Earnings Yield | -30.73 |